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the index vessel in over half of the cases. The original results 
from the OPTIMA trial likewise suggested that an immedi-
ate invasive treatment of NSTE-ACS patients is associated 
with a poorer 30-day outcome and conveys an increased rate 
of peri-procedural myocardial infarction [3]. Whereas the 
potential early detrimental effects of immediate interven-
tion are likely to be attributed to increased thrombus load 
with inherent phenomena such as no-reflow and thrombotic 
side branch occlusion provoked by the procedure, it is less 
clear how long-term prognosis 30 days after hospitalisation 
could be related to the timing of the index procedure. Pos-
tulated mechanisms include the fact that deferred interven-
tion may result in restoration of vascular tone and thus may 
facilitate more optimal sizing of stents potentially prevent-
ing late stent thrombosis and restenosis. On the other hand, 
it should be acknowledged that the study is hampered by 
uneven distribution of baseline patient characteristics. The 
immediate treatment arm comprised significantly more 
patients who had undergone previous bypass surgery indi-
cating a more advanced stage of coronary artery disease. In 
fact, half of the late myocardial infarctions in the immediate 
arm occurred in non-index vessels with no apparent relation 
to the initial procedure. Furthermore, the current data are 
not in line with previous studies such as the ABOARD trial, 
which failed to display any differences in outcome of imme-
diate vs. deferred intervention to the next working day [4].
The debate pertaining to the optimal timing of interven-
tion in patients presenting with NSTE-ACS will therefore 
continue as results from ongoing trials as the OPTIMA 2 
and TRANSIENT are eagerly awaited [5]. In the meantime, 
it is reassuring to realise that acute interventions in these 
patients are not mandatory and medical stabilisation with 
antithrombotic agents appears to be non-inferior and may 
even be associated with improved short- and long-term out-
come. This is particularly convenient from a logistical point 
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Primary percutaneous coronary intervention (PCI) has 
unequivocally proven to be the optimal reperfusion treat-
ment strategy in patients with ST-segment elevation myo-
cardial infarction, whereby timing is simply an issue of the 
sooner the better. In recent years, it has additionally become 
apparent that an early invasive approach is also beneficial in 
patients with non-ST-segment elevation acute coronary syn-
dromes (NSTE-ACS). The definition of early in this subset 
of patients is, however, ambiguous. Based on risk stratifica-
tion parameters, high-risk patients (i.e. GRACE score > 140) 
are preferably subjected to invasive diagnosis and potential 
PCI within 24 h whereas in low-intermediate risk patients, 
urgency of coronary angiography is of lesser importance 
and advocated to occur within a timeframe of 72 h after the 
initial diagnosis. These guidelines dictate the timeframe in 
which the invasive approach should be employed at the lat-
est but do not indicate whether an immediate treatment may 
yield an even better outcome [1].
In this issue of the Netherlands Heart Journal, Ooster-
werff et al. report on the long-term follow-up data of the 
OPTIMA trial exploring the effects of an immediate vs. 
deferred PCI in NSTE-ACS patients with coronary anatomy 
amenable for percutaneous intervention [2]. Even though 
underpowered to draw definite conclusions, the results are 
intriguing. After 5 years, there was no difference in the 
combined endpoint but late myocardial infarction (> 30 
days after randomisation) was observed significantly more 
frequently in the immediate treatment arm and was linked to 
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of view as it avoids the necessity for patients to be rushed 
to centres with 24/7 PCI coverage and they can safely be 
hospitalised at local community hospitals for initial medi-
cal treatment prior to coronary angiography in the ensuing 
days [6]. This prevents a substantial additional burden on 
catheterisation laboratory facilities, which was one of the 
main reasons for the slow inclusion rate of the OPTIMA 
trial and ultimately resulted in termination of the trial before 
the required number of patients was enrolled [3]. Another 
pivotal issue that arises is whether coronary angiography 
should be restricted to PCI centres in these patients. The 
OPTIMA trial revealed that 57 % of patients displayed coro-
nary pathology amenable for ad hoc PCI. Mere diagnostic 
coronary angiography without the ability to perform inter-
vention in NSTE-ACS therefore results in unnecessary sec-
ondary procedures and treatment delay in the majority of 
patients. These arguments could act as a plea to transfer all 
NSTE-ACS patients within 24 or 72 h, depending on the 
GRACE risk score, to interventional clinics in order to offer 
appropriate treatment in a timely fashion. This will require 
even closer collaboration between PCI centres and their sat-
ellite partners to further optimise patient care. A goal, none-
theless, that is worth pursuing.
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